

# Safety and effectiveness of guselkumab on moderate to severe plaque psoriasis

E. Tejedor Tejada<sup>1</sup>, M. Rodríguez Goicoechea<sup>2</sup>, Á. López Moreno<sup>2</sup>, N. García Gómez<sup>2</sup>, MJ. Barbero Hernández<sup>2</sup>, F. Horno Ureña<sup>2</sup>


1. Clínic Hospital of Barcelona, 2. University Hospital Complex of Jaén

## Background and importance

In recent years, anti-IL-23 drugs have emerged as a new therapeutic option for plaque psoriasis.

## Aim and Objectives

To evaluate safety and effectiveness of guselkumab in moderate to severe plaque psoriasis.



## MATERIALS AND METHODS

Multicentric, retrospective and observational study made with plaque psoriasis patients with active treatment with guselkumab.

Time: June 2021- June 2022.

Tools




## RESULTS

Patients N=49

Sex: 59,2% men

Average age: GUS 50,9+/- 12.1 years

Main pretreatment



- Adalimumab
- Secukinumab
- Ustekinumab

	Week 0	23 weeks	40 weeks	72 weeks
BSA	13,6±10.27SD	3.9±9.27SD	1.8±3.28SD	0.9±1.55SD
PASI	9.7±6.68SD	2.9±4.17SD	1.8±3.3SD	0.5±0.91SD

PASI90  
73%



## Conclusion and Relevance

it is possible to evaluate guselkumab as an effective and safe alternative in the treatment of moderate to severe psoriasis resistant to conventional treatments.

## REFERENCES

Puig L. Guselkumab for the treatment of adults with moderate to severe plaque psoriasis. Expert Rev Clin Immunol. 2019 Jun;15(6):589-597. doi: 10.1080/1744666X.2019.1601014. Epub 2019 Apr 12. PMID: 30920855.

L-04

IMMUNOSUPPRESSANTS

Investigator contact: tejedor@clinic.cat

4CPS-133